Cetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCC
Clinical trial NCT06978829 · RECRUITING
Trial details
- NCT number
- NCT06978829
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-03-01
- Primary completion
- 2027-03-31
- Enrollment
- 42
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.